Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Merck Serono Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Australian Public Assessment Report (AusPAR) (9)
Cancellation by sponsor (2)
Prescription medicine registration (1)

Date

2019 (2)
2018 (2)
2014 (1)
2013 (2)
2011 (3)
2010 (2)

Results for "[search-keyword]"

Search

Sponsor content

12 result(s) found, displaying 11 to 12

AusPAR: Cetuximab

15 January 2010

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Cetuximab
AusPAR: Follitropin alfa (rch) / Lutropin alfa (rch)

11 January 2010

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Follitropin alfa (rch) / Lutropin alfa (rch)

Pages

First page
Previous page
Page 1
Current page 2

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Merck Serono Australia Pty Ltd

Type

Date

AusPAR: Cetuximab

AusPAR: Follitropin alfa (rch) / Lutropin alfa (rch)

Help us improve the Therapeutic Goods Administration site